Kamada (KMDA) Expected to Announce Quarterly Earnings on Wednesday

Kamada (NASDAQ:KMDA) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $46.7220 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Kamada had a return on equity of 7.72% and a net margin of 11.19%.The business had revenue of $44.68 million for the quarter, compared to analyst estimates of $145.07 million. On average, analysts expect Kamada to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kamada Price Performance

Shares of KMDA stock opened at $8.21 on Wednesday. The business’s fifty day moving average price is $8.53 and its 200 day moving average price is $7.82. Kamada has a 1-year low of $6.50 and a 1-year high of $9.35. The firm has a market capitalization of $472.16 million, a PE ratio of 23.46, a P/E/G ratio of 0.63 and a beta of 0.86.

Kamada Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a dividend of $0.25 per share. This represents a yield of 305.0%. The ex-dividend date of this dividend was Monday, March 23rd. Kamada’s dividend payout ratio is currently 54.29%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on KMDA shares. Stifel Nicolaus set a $11.00 price objective on Kamada in a report on Wednesday, March 11th. Benchmark reissued a “buy” rating on shares of Kamada in a report on Thursday, March 12th. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered Kamada from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Kamada currently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Institutional Trading of Kamada

Several large investors have recently bought and sold shares of the company. Marshall Wace LLP grew its holdings in Kamada by 25.9% in the fourth quarter. Marshall Wace LLP now owns 196,954 shares of the biotechnology company’s stock valued at $1,390,000 after purchasing an additional 40,514 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Kamada by 43.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 167,521 shares of the biotechnology company’s stock valued at $1,183,000 after acquiring an additional 50,608 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of Kamada by 4.3% during the third quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after acquiring an additional 4,504 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Kamada during the first quarter valued at $582,000. Finally, Bank of America Corp DE boosted its stake in shares of Kamada by 201.0% during the third quarter. Bank of America Corp DE now owns 61,565 shares of the biotechnology company’s stock valued at $427,000 after acquiring an additional 41,111 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.